| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 201.89% | Piper Sandler | $7 → $8 | Maintains | Overweight |
| 06/26/2023 | 277.36% | Oppenheimer | → $10 | Assumes | Outperform → Outperform |
| 06/15/2023 | 201.89% | Stifel | → $8 | Reiterates | Buy → Buy |
| 05/15/2023 | 466.04% | JMP Securities | → $15 | Reiterates | Outperform → Outperform |
| 03/22/2023 | 201.89% | Stifel | $9 → $8 | Maintains | Buy |
| 03/22/2023 | 277.36% | Oppenheimer | → $10 | Reiterates | → Outperform |
| 11/21/2022 | 164.15% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 08/24/2022 | 277.36% | Oppenheimer | $26 → $10 | Maintains | Outperform |
| 03/21/2022 | 881.13% | Oppenheimer | $32 → $26 | Maintains | Outperform |
| 03/18/2022 | 881.13% | Craig-Hallum | $28 → $26 | Maintains | Buy |
| 11/24/2020 | 1032.08% | Berenberg | → $30 | Initiates Coverage On | → Buy |
| 05/20/2020 | 1032.08% | Stifel | $25 → $30 | Maintains | Buy |
| 05/20/2020 | 1107.55% | Oppenheimer | $27 → $32 | Maintains | Outperform |
| 04/21/2020 | 843.4% | Stifel | $21 → $25 | Maintains | Buy |
| 04/09/2020 | 692.45% | Stifel | → $21 | Initiates Coverage On | → Buy |
| 03/06/2020 | 1032.08% | JMP Securities | $22 → $30 | Maintains | Outperform |
| 02/25/2020 | 918.87% | Oppenheimer | → $27 | Initiates Coverage On | → Outperform |
| 01/28/2020 | 881.13% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 01/22/2020 | 730.19% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 07/26/2019 | 390.57% | Baird | → $13 | Initiates Coverage On | → Outperform |
What is the target price for Cue Biopharma (CUE)?
The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Piper Sandler on November 6, 2023. The analyst firm set a price target for $8.00 expecting CUE to rise to within 12 months (a possible 201.89% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cue Biopharma (CUE)?
The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Piper Sandler, and Cue Biopharma maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Cue Biopharma (CUE) correct?
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a maintained with a price target of $7.00 to $8.00. The current price Cue Biopharma (CUE) is trading at is $2.65, which is out of the analyst's predicted range.